Prostate Cancer - Episode 7
During this segment, David Quinn, MD, and Michael Kolodziej, MD, discuss the challenges clinicians face when developing a drug-sequencing plan for patients with castration-resistant prostate cancer.
Dr Quinn explains that because not all patients respond to the same types of therapy, there is a need for data that reveals the appropriateness of agents suggested in step therapy plans.
To address this challenge, he suggests that new clinical trials test comparative effectiveness, which he believes can help determine response rates for specific groups of patients.
Dr Kolodziej argues that receiving this data will take too long, and suggests receiving aid from professional services that can structure current data into an actionable format. He explains that this may help provide quick answers about step therapy and can improve the clinician’s decision-making process.